BioMarin Q4 Earnings & Sales Top Estimates, Stock Up on Upbeat '25 View

BioMarin Pharmaceutical (BMRN) reported fourth-quarter adjusted earnings per share of 92 cents, which beat the Zacks Consensus Estimate of 73 cents. Quarterly earnings rose 88% year over year, driven by higher product sales and lower operating expenses.Total revenues were $747.3 million, which rose 16% year over year on a reported basis and 21% on a constant-currency basis. Strong sales of Voxzogo drove this upside. The top line beat the Zacks Consensus Estimate of $711.9 million.See the Zacks Earnings Cale ...